CD24 is a genetic modifier for risk and progression of prostate cancer.

CD24 plays an oncogenic role in the onset and progression of various human cancers, including prostate cancer. In the present study, we identified two linkage disequilibrium blocks with four recombination hotspot motifs in human CD24 locus. To elucidate whether genetic variants of CD24 associated with susceptibility to prostate cancer and its disease status, we conducted a case-control association study with two P170 C/T and P-534 A/C polymorphisms of CD24 in 590 patients with prostate cancer and 590 healthy controls. A significant increased risk of prostate cancer was found in men with the P170(T/T) genotype over the P170(C/C) genotype (odd ratio = 1.74, 95% confidence interval = 1.16-2.63, P = 0.008), and in men with the P-534(C/C) genotype over the P-534(A/A) genotype (odd ratio = 1.47, 95% confidence interval = 1.18-2.26, P = 0.003). Cochran-Armitage trend analysis showed that the P170(T) allele was significantly correlated with an increased risk of prostate cancer progression (P = 0.029, trend between genotypes and stages) and this observation was also validated in an independent sample cohort. Next, we found that tumors with P170(T) or P-534(C) alleles had more 2-fold increased protein expressions of CD24 as compared to those with P170(C) or P-534(A) alleles, respectively. Likewise, tumors with a combination of P170(T/T) and P-534(C/C) genotypes were associated with a high mRNA level of CD24. Our data suggest a significant association of CD24 genetic variants with prostate cancer onset and progression, which provides new insight into molecular genetics of prostate cancer; however, these findings need to be validated in multiple independent cohorts. This article is protected by copyright. All rights reserved.

Molecular carcinogenesis. 2016 Jul 05 [Epub ahead of print]

Yifan Zhang, Bingjin Li, Xingyi Zhang, Guru P Sonpavde, Kenneth Jiao, Andrea Zhang, Guangxin Zhang, Mei Sun, Chengjing Chu, Feng Li, Lizhong Wang, Ranji Cui, Runhua Liu

Department of Thoracic Surgery, the Second Hospital of Jilin University, 218 Ziqiang street, Changchun, 130041, PR China., Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, Second Hospital of Jilin University, Changchun, 130041, PR China., Department of Thoracic Surgery, the Second Hospital of Jilin University, 218 Ziqiang street, Changchun, 130041, PR China., Department of Internal Medicine, Section of Medical Oncology, University of Alabama at Birmingham, Birmingham, Alabama, 35294., Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, 35294., Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, 35294., Department of Thoracic Surgery, the Second Hospital of Jilin University, 218 Ziqiang street, Changchun, 130041, PR China., Department of Pathology, the Second Hospital of Jilin University, 218 Ziqiang street, Changchun, 130041, PR China., Department of Health and Social Science, Guangdong Medical College, Dongguan, 523808, PR China., Anshan Normal University Affiliated Health School, Anshan, 114044, PR China., Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, 35294., Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, Second Hospital of Jilin University, Changchun, 130041, PR China., Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, 35294.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe